Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative and inflammatory diseases, has closed a $12 million Series A financing round led by Double Point Ventures, with participation from both new and existing investors.
Proceeds will support the advancement of the company’s lead program, LHP588, and continued pipeline expansion. Lighthouse is currently conducting the SPRING trial, a Phase 2 clinical study evaluating LHP588 in patients with P. gingivalis-positive mild to moderate Alzheimer’s disease. The trial is also supported by a $49.2 million grant from the National Institute on Aging, part of the National Institutes of Health.
LHP588 is an oral, once-daily small-molecule therapy targeting P. gingivalis, a bacterium associated with periodontal disease that is increasingly implicated in Alzheimer’s disease progression. The SPRING trial is a double-blind placebo-controlled study currently enrolling participants across the United States.
Lighthouse’s approach centers on targeting a defined subset of Alzheimer’s patients, aiming to bring greater precision to a disease area where broad-population treatments have historically struggled to demonstrate meaningful clinical benefit.
In connection with the financing, Campbell Murray, a partner at Double Point Ventures, will join Lighthouse’s Board of Directors. Murray brings experience in life sciences investing, company building, and clinical-stage development strategy.
KEY QUOTES:
“Lighthouse is advancing a differentiated approach based on compelling scientific and clinical data. This financing, together with the support from the NIA, gives Lighthouse the resources to efficiently execute the SPRING trial and advance LHP588 toward late-stage development. By targeting a defined subset of Alzheimer’s disease, we aim to bring a more precise and effective therapeutic approach to patients.”
Casey Lynch, Chief Executive Officer, Lighthouse Pharmaceuticals
“Lighthouse is pursuing a distinctive and focused approach in Alzheimer’s disease. With LHP588, the company is targeting an important and underexplored biological driver in a defined patient population. We believe the SPRING trial has the potential to generate clinically meaningful data and to further establish Lighthouse as an innovative company in neurodegeneration.”
Campbell Murray, Partner, Double Point Ventures
